Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Debt Issuances (2020 - 2024)

Xeris Biopharma Holdings (XERS) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $50.0 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Long-Term Debt Issuances changed N/A year-over-year to $50.0 million, compared with a TTM value of $50.0 million through Dec 2024, changed N/A, and an annual FY2024 reading of $50.0 million, changed N/A over the prior year.
  • Long-Term Debt Issuances was $50.0 million for Q1 2024 at Xeris Biopharma Holdings, up from $48.9 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $97.3 million in Q1 2022 and bottomed at $3.5 million in Q4 2020.
  • Average Long-Term Debt Issuances over 3 years is $49.9 million, with a median of $49.5 million recorded in 2022.